Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MQX-503 · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| MQX-503 | DRUG | - |
Inclusion Criteria: * Outpatients, 18 to 75 years * Clinical Diagnosis of Raynaud's, or observed event by study physician, or symptoms with reduced blood flow as meausred using laser doppler equipment * Agree to have test gels applied to finger * Discontinue current vasodialator therapeis for Rayna...
MQX-503 is an investigational small molecule being developed for the treatment of Raynaud's disease, a condition where blood vessels overreact to cold or stress, causing reduced blood flow to extremities. It is formulated as a topical gel and is currently in Phase 2 clinical development.
MQX-503 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The drug is an investigational small molecule being studied for the treatment of Raynaud's disease.
MQX-503 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy for treating Raynaud's disease.
MQX-503 has one completed Phase 2 clinical trial, identified as NCT00378521. This was a dose-response study of a topical gel for the treatment of Raynaud's phenomenon, enrolling 15 participants in the United States. The trial was randomized and double-blind, though it did not use a control group.
MQX-503 is the primary name for this investigational drug. No alternative names have been established for it in the available clinical trial information. It is being studied specifically as a topical gel for Raynaud's disease.